{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T12:30:45Z","timestamp":1774355445211,"version":"3.50.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41433-026-04254-1","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T06:42:48Z","timestamp":1769064168000},"page":"603-610","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of diplopia among giant cell arteritis patients: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0571-2894","authenticated-orcid":false,"given":"Thanansayan","family":"Dhivagaran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahad R.","family":"Butt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Nasri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pranshu","family":"Maini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2306-1547","authenticated-orcid":false,"given":"Erin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7069-3162","authenticated-orcid":false,"given":"Brendan K.","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun","family":"Sundaram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0623-0934","authenticated-orcid":false,"given":"Edsel B.","family":"Ing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul A.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"4254_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ncl.2019.01.008","volume":"37","author":"DS Younger","year":"2019","unstructured":"Younger DS. Giant cell arteritis. Neurologic Clin. 2019;37:335\u201344. https:\/\/doi.org\/10.1016\/j.ncl.2019.01.008.","journal-title":"Neurologic Clin"},{"key":"4254_CR2","unstructured":"Hocaoglu M, Mikdashi J, Perry J, Hong C. Association of HLA-DRB1 and ANKRD55\/IL6ST regions with polymyalgia rheumatica diagnosis: a genome wide association study from UK Biobank and FinnGen. Arthritis Rheumatol. 2023;75:43\u201345"},{"key":"4254_CR3","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.ajhg.2015.02.009","volume":"96","author":"FD Carmona","year":"2015","unstructured":"Carmona FD, Mackie SL, Mart\u00edn JE, Taylor JC, Vaglio A, Eyre S, et al. A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility. Am J Hum Genet. 2015;96:565\u201380. https:\/\/doi.org\/10.1016\/j.ajhg.2015.02.009.","journal-title":"Am J Hum Genet"},{"key":"4254_CR4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/gerona\/gln030","volume":"64","author":"RW Crow","year":"2009","unstructured":"Crow RW, Katz BJ, Warner JE, Alder SC, Zhang K, Schulman S, et al. Giant cell arteritis and mortality. J Gerontol A Biol Sci Med Sci. 2009;64:365\u20139. https:\/\/doi.org\/10.1093\/gerona\/gln030.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"4254_CR5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.4103\/ijo.IJO_1681_20","volume":"69","author":"SS Hayreh","year":"2021","unstructured":"Hayreh SS. Giant cell arteritis: its ophthalmic manifestations. Indian J Ophthalmol. 2021;69:227\u201335. https:\/\/doi.org\/10.4103\/ijo.IJO_1681_20.","journal-title":"Indian J Ophthalmol"},{"key":"4254_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/WNO.0000000000000656","volume":"39","author":"AG Ross","year":"2019","unstructured":"Ross AG, Jivraj I, Rodriguez G, Pistilli M, Chen JJ, Sergott RC, et al. Retrospective, multicenter comparison of the clinical presentation of patients presenting with diplopia from giant cell arteritis vs other causes. J Neuroophthalmol. 2019;39:8\u201313. https:\/\/doi.org\/10.1097\/WNO.0000000000000656.","journal-title":"J Neuroophthalmol"},{"key":"4254_CR7","doi-asserted-by":"publisher","first-page":"3207EP","DOI":"10.1007\/s10067-021-05643-5","volume":"40","author":"H Baalbaki","year":"2021","unstructured":"Baalbaki H, Jalaledin D, Lachance C, Febrer G, Rheaume M, Makhzoum JP. Characterization of visual manifestations and identification of risk factors for permanent vision loss in patients with giant cell arteritis. Clin Rheumatol. 2021;40:3207EP\u20133217. https:\/\/doi.org\/10.1007\/s10067-021-05643-5.","journal-title":"Clin Rheumatol"},{"key":"4254_CR8","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/art.1780370705","volume":"37","author":"\u00d3 Baldursson","year":"1994","unstructured":"Baldursson \u00d3, Steinsson K, Bj\u00f6rnsson J, Lie JT. Giant cell arteritis in Iceland. Arthritis Rheum. 1994;37:1007\u201312. https:\/\/doi.org\/10.1002\/art.1780370705.","journal-title":"Arthritis Rheum"},{"key":"4254_CR9","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/0021-9681(73)90062-3","volume":"26","author":"DG Beevers","year":"1973","unstructured":"Beevers DG, Harpur JE, Turk KAD. Giant cell arteritis \u2014 the need for prolonged treatment. J Chronic Dis. 1973;26:571\u201384. https:\/\/doi.org\/10.1016\/0021-9681(73)90062-3.","journal-title":"J Chronic Dis"},{"key":"4254_CR10","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/art.1780240706","volume":"24","author":"B-\u00c5 Bengtsson","year":"1981","unstructured":"Bengtsson B-\u00c5, Malmvall B-E. The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. Arthritis Rheum. 1981;24:899\u2013904. https:\/\/doi.org\/10.1002\/art.1780240706.","journal-title":"Arthritis Rheum"},{"key":"4254_CR11","doi-asserted-by":"publisher","first-page":"75EP","DOI":"10.1080\/01658107.2021.1965627","volume":"46","author":"CM Castillejo Becerra","year":"2022","unstructured":"Castillejo Becerra CM, Crowson CS, Koster MJ, Warrington KJ, Bhatti MT, Chen JJ. Population-based rate and patterns of diplopia in giant cell arteritis. Neuro Ophthalmol. 2022;46:75EP\u201379. https:\/\/doi.org\/10.1080\/01658107.2021.1965627.","journal-title":"Neuro Ophthalmol"},{"key":"4254_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/WNO.0000000000001912","volume":"44","author":"T Chazal","year":"2024","unstructured":"Chazal T, Clavel G, Leturcq T, Philibert M, Lecler A, Vignal-Clermont C. Characteristics and prognosis of binocular diplopia in patients with giant cell arteritis. J Neuro Ophthalmol. 2024;44:87\u201391. https:\/\/doi.org\/10.1097\/WNO.0000000000001912.","journal-title":"J Neuro Ophthalmol"},{"key":"4254_CR13","doi-asserted-by":"publisher","first-page":"1789EP","DOI":"10.1007\/s00296-019-04422-5","volume":"39","author":"CS Chean","year":"2019","unstructured":"Chean CS, Prior JA, Helliwell T, Belcher J, Mackie SL, Hider SL, et al. Characteristics of patients with giant cell arteritis who experience visual symptoms. Rheumatol Int. 2019;39:1789EP\u20131796. https:\/\/doi.org\/10.1007\/s00296-019-04422-5.","journal-title":"Rheumatol Int"},{"key":"4254_CR14","doi-asserted-by":"publisher","first-page":"885463","DOI":"10.3389\/fmed.2022.885463","volume":"9","author":"Q Chen","year":"2022","unstructured":"Chen Q, Chen W, Feng C, Gong D, Zhang J, Bi Y, et al. Giant cell arteritis presenting with ocular symptoms: clinical characteristics and multimodal imaging in a Chinese case series. Front Med. 2022;9:885463. https:\/\/doi.org\/10.3389\/fmed.2022.885463.","journal-title":"Front Med"},{"key":"4254_CR15","doi-asserted-by":"publisher","first-page":"26EP","DOI":"10.1002\/1529-0131(199801)41:1<26::AID-ART4>3.0.CO;2-0","volume":"41","author":"MC Cid","year":"1998","unstructured":"Cid MC, Font C, Oristrell J, de la Sierra A, Coll-Vinent B, L\u00f3pez-Soto A, et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum. 1998;41:26EP\u201332.","journal-title":"Arthritis Rheum"},{"key":"4254_CR16","doi-asserted-by":"publisher","first-page":"335EP","DOI":"10.1016\/j.semarthrit.2019.09.008","volume":"50","author":"A Dumont","year":"2020","unstructured":"Dumont A, Lecannuet A, Boutemy J, Maign\u00e9 G, Martin-Silva N, Deshayes S, et al. Characteristics and outcomes of patients with ophthalmologic involvement in giant-cell arteritis: a case-control study. Semin Arthritis Rheum. 2020;50:335EP\u2013341. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.09.008.","journal-title":"Semin Arthritis Rheum"},{"key":"4254_CR17","first-page":"S96","volume":"31","author":"M Figus","year":"2013","unstructured":"Figus M, Talarico R, Posarelli C, D\u2019Ascanio A, Elefante E, Bombardieri S. Ocular involvement in giant cell arteritis. Clin Exp Rheumatol. 2013;31:S96.","journal-title":"Clin Exp Rheumatol"},{"key":"4254_CR18","doi-asserted-by":"publisher","first-page":"113EP","DOI":"10.1038\/eye.2016.199","volume":"31","author":"ST Garrity","year":"2017","unstructured":"Garrity ST, Pistilli M, Vaphiades MS, Richards NQ, Subramanian PS, Rosa PR, et al. Ophthalmic presentation of giant cell arteritis in African-Americans. Eye. 2017;31:113EP\u2013118. https:\/\/doi.org\/10.1038\/eye.2016.199.","journal-title":"Eye"},{"key":"4254_CR19","doi-asserted-by":"publisher","first-page":"537EP","DOI":"10.1093\/rheumatology\/kep011","volume":"48","author":"J Geiger","year":"2009","unstructured":"Geiger J, Ness T, Uhl M, Lagr\u00e8ze WA, Vaith P, Langer M, et al. Involvement of the ophthalmic artery in giant cell arteritis visualized by 3T MRI. Rheumatology. 2009;48:537EP\u2013541. https:\/\/doi.org\/10.1093\/rheumatology\/kep011.","journal-title":"Rheumatology"},{"key":"4254_CR20","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1177\/112067219700700412","volume":"7","author":"S Glutz von Blotzheim","year":"1997","unstructured":"Glutz von Blotzheim S, Borruat FX. Neuro-ophthalmic complications of biopsy-proven giant cell arteritis. Eur J Ophthalmol. 1997;7:375\u201382. https:\/\/doi.org\/10.1177\/112067219700700412.","journal-title":"Eur J Ophthalmol"},{"key":"4254_CR21","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1002\/1529-0131(199808)41","volume":"41","author":"MA Gonz\u00e1lez-Gay","year":"1998","unstructured":"Gonz\u00e1lez-Gay MA, Blanco R, Rodr\u00edguez-Valverde V, Mart\u00ednez-Taboada VM, Delgado-Rodriguez M, Figueroa M, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum. 1998;41:1497\u2013504. https:\/\/doi.org\/10.1002\/1529-0131(199808)41.","journal-title":"Arthritis Rheum"},{"key":"4254_CR22","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1136\/bmj.282.6260.269","volume":"282","author":"E Graham","year":"1981","unstructured":"Graham E, Holland A, Avery A, Russell RW. Prognosis in giant-cell arteritis. Br Med J. 1981;282:269\u201371. https:\/\/doi.org\/10.1136\/bmj.282.6260.269.","journal-title":"Br Med J"},{"key":"4254_CR23","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.3899\/jrheum.130983","volume":"41","author":"M Haering","year":"2014","unstructured":"Haering M, Holbro A, Todorova MG, Aschwanden M, Kesten F, Berger CT, et al. Incidence and prognostic implications of diplopia in patients with giant cell arteritis. J Rheumatol. 2014;41:1562\u20134. https:\/\/doi.org\/10.3899\/jrheum.130983.","journal-title":"J Rheumatol"},{"key":"4254_CR24","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/s0002-9394(99)80192-5","volume":"125","author":"SS Hayreh","year":"1998","unstructured":"Hayreh SS, Podhajsky PA, Zimmerman B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol. 1998;125:509\u201320. https:\/\/doi.org\/10.1016\/s0002-9394(99)80192-5.","journal-title":"Am J Ophthalmol"},{"key":"4254_CR25","doi-asserted-by":"publisher","first-page":"233EP","DOI":"10.1097\/MD.0b013e318145275c","volume":"86","author":"J Hern\u00e1ndez-Rodr\u00edguez","year":"2007","unstructured":"Hern\u00e1ndez-Rodr\u00edguez J, Font C, Garc\u00eda-Mart\u00ednez A, Esp\u00edgol-Frigol\u00e9 G, Sanmart\u00ed R, Ca\u00f1ete JD, et al. Development of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica: Study of a series of 100 patients. Medicine. 2007;86:233EP\u2013241. https:\/\/doi.org\/10.1097\/MD.0b013e318145275c.","journal-title":"Medicine"},{"key":"4254_CR26","doi-asserted-by":"publisher","first-page":"2953EP","DOI":"10.1093\/rheumatology\/keaa058","volume":"59","author":"A Hocevar","year":"2020","unstructured":"Hocevar A, Jese R, Tomsic M, Rotar Z. Risk factors for severe cranial ischaemic complications in giant cell arteritis. Rheumatology. 2020;59:2953EP\u20132959. https:\/\/doi.org\/10.1093\/rheumatology\/keaa058.","journal-title":"Rheumatology"},{"key":"4254_CR27","doi-asserted-by":"publisher","first-page":"490EP","DOI":"10.1212\/WNL.10.5.490","volume":"10","author":"RWHN Horst","year":"1960","unstructured":"Horst RWHN, Brown JR, Wagener HP, Shick RM. Neurologic aspects of temporal arteritis. Neurology. 1960;10:490EP\u2013498.","journal-title":"Neurology"},{"key":"4254_CR28","doi-asserted-by":"publisher","first-page":"439EP","DOI":"10.1007\/s00296-020-04730-1","volume":"41","author":"B Ince","year":"2021","unstructured":"Ince B, Artan S, Yalcinkaya Y, Artim-Esen B, Gul A, Ocal L, et al. Long-term follow-up of 89 patients with giant cell arteritis: a retrospective observational study on disease characteristics, flares and organ damage. Rheumatol Int. 2021;41:439EP\u2013448. https:\/\/doi.org\/10.1007\/s00296-020-04730-1.","journal-title":"Rheumatol Int"},{"key":"4254_CR29","doi-asserted-by":"publisher","first-page":"2031EP","DOI":"10.2147\/OPTH.S151385","volume":"11","author":"EB Ing","year":"2017","unstructured":"Ing EB, Lahaie Luna G, Toren A, Ing R, Chen JJ, Arora N, et al. Multivariable prediction model for suspected giant cell arteritis: development and validation. Clin Ophthalmol. 2017;11:2031EP\u20132042. https:\/\/doi.org\/10.2147\/OPTH.S151385.","journal-title":"Clin Ophthalmol"},{"key":"4254_CR30","doi-asserted-by":"publisher","first-page":"421EP","DOI":"10.2147\/OPTH.S193460","volume":"13","author":"EB Ing","year":"2019","unstructured":"Ing EB, Miller NR, Nguyen A, Su W, Bursztyn L, Poole M, et al. Neural network and logistic regression diagnostic prediction models for giant cell arteritis: development and validation. Clin Ophthalmol. 2019;13:421EP\u2013430. https:\/\/doi.org\/10.2147\/OPTH.S193460.","journal-title":"Clin Ophthalmol"},{"key":"4254_CR31","doi-asserted-by":"publisher","first-page":"120222","DOI":"10.1016\/j.jns.2022.120222","volume":"436","author":"M Issa","year":"2022","unstructured":"Issa M, Donaldson L, Jeeva-Patel T, Margolin E. Ischemic ocular manifestations of giant cell arteritis: a Canadian case series. J Neurological Sci. 2022;436:120222. https:\/\/doi.org\/10.1016\/j.jns.2022.120222.","journal-title":"J Neurological Sci"},{"key":"4254_CR32","doi-asserted-by":"publisher","first-page":"2055EP","DOI":"10.1007\/s10067-017-3619-4","volume":"36","author":"S Jobard","year":"2017","unstructured":"Jobard S, Magnant J, Blasco H, Ferreira-Maldent N, Griffoul I, Diot E, et al. Quality of life of patients treated for giant cell arteritis: a case-control study. Clin Rheumatol. 2017;36:2055EP\u20132062. https:\/\/doi.org\/10.1007\/s10067-017-3619-4.","journal-title":"Clin Rheumatol"},{"key":"4254_CR33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/003693307902400203","volume":"24","author":"F Jonasson","year":"1979","unstructured":"Jonasson F, Cullen JF, Elton RA. Temporal arteritis: a 14-year epidemiological, clinical and prognostic study. Scott Med J. 1979;24:111\u20137. https:\/\/doi.org\/10.1177\/003693307902400203.","journal-title":"Scott Med J"},{"key":"4254_CR34","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0161-6420(94)31102-X","volume":"101","author":"GT Liu","year":"1994","unstructured":"Liu GT, Glaser JS, Schatz NJ, Smith JL. Visual morbidity in giant cell arteritis: clinical characteristics and prognosis for vision. Ophthalmology. 1994;101:1779\u201385. https:\/\/doi.org\/10.1016\/S0161-6420(94)31102-X.","journal-title":"Ophthalmology"},{"key":"4254_CR35","doi-asserted-by":"publisher","first-page":"1759720","DOI":"10.1177\/1759720X221113747","volume":"14","author":"J Loricera","year":"2022","unstructured":"Loricera J, Casta\u00f1eda S, Moriano C, Narv\u00e1ez J, Aldasoro V, Maiz O, et al. Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients. Therapeutic Adv Musculoskelet Dis. 2022;14:1759720. https:\/\/doi.org\/10.1177\/1759720X221113747.","journal-title":"Therapeutic Adv Musculoskelet Dis"},{"key":"4254_CR36","doi-asserted-by":"publisher","first-page":"732934","DOI":"10.3389\/fmed.2021.732934","volume":"8","author":"A Mahr","year":"2021","unstructured":"Mahr A, Hachulla E, de Boysson H, Guerroui N, H\u00e9ron E, Vinzio S, et al. Presentation and real-world management of giant cell arteritis (Artemis study). Front Med. 2021;8:732934 https:\/\/doi.org\/10.3389\/fmed.2021.732934.","journal-title":"Front Med"},{"key":"4254_CR37","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/MD.0b013e3181af70c1","volume":"88","author":"K Maksimowicz-McKinnon","year":"2009","unstructured":"Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Takayasu arteritis and giant cell arteritis: a spectrum within the same disease? Medicine. 2009;88:221\u20136. https:\/\/doi.org\/10.1097\/MD.0b013e3181af70c1.","journal-title":"Medicine"},{"key":"4254_CR38","doi-asserted-by":"publisher","first-page":"4472EP","DOI":"10.1007\/s00330-020-07595-x","volume":"31","author":"S Mournet","year":"2021","unstructured":"Mournet S, Sen\u00e9 T, Charbonneau F, Poillon G, Vignal C, Clavel G, et al. High-resolution MRI demonstrates signal abnormalities of the 3rd cranial nerve in giant cell arteritis patients with 3rd cranial nerve impairment. Eur Radiol. 2021;31:4472EP\u20134480. https:\/\/doi.org\/10.1007\/s00330-020-07595-x.","journal-title":"Eur Radiol"},{"key":"4254_CR39","doi-asserted-by":"publisher","first-page":"1228EP","DOI":"10.1111\/imj.16419","volume":"54","author":"L Robinson","year":"2024","unstructured":"Robinson L, Hamden M, Griggs K, Simon S, Hill C, Limaye V, et al. Tocilizumab use in giant cell arteritis: comparing Pharmaceutical Benefits Scheme eligible and ineligible cases in South Australia. Intern Med J. 2024;54:1228EP\u20131232. https:\/\/doi.org\/10.1111\/imj.16419.","journal-title":"Intern Med J"},{"key":"4254_CR40","doi-asserted-by":"publisher","first-page":"293EP","DOI":"10.1002\/art.21075","volume":"53","author":"C Salvarani","year":"2005","unstructured":"Salvarani C, Cimino L, Macchioni P, Consonni D, Cantini F, Bajocchi G, et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Care Res. 2005;53:293EP\u2013297. https:\/\/doi.org\/10.1002\/art.21075.","journal-title":"Arthritis Care Res"},{"key":"4254_CR41","doi-asserted-by":"publisher","first-page":"1310EP","DOI":"10.3899\/jrheum.2022-1214","volume":"50","author":"MJ Samec","year":"2023","unstructured":"Samec MJ, Rakholiya J, Langenfeld H, Crowson CS, Abril A, Wang B, et al. Relapse risk and safety of long-term tocilizumab use among patients with giant cell arteritis: a single-enterprise cohort study. J Rheumatol. 2023;50:1310EP\u20131317. https:\/\/doi.org\/10.3899\/jrheum.2022-1214.","journal-title":"J Rheumatol"},{"key":"4254_CR42","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1093\/rheumatology\/ken515","volume":"48","author":"WA Schmidt","year":"2009","unstructured":"Schmidt WA, Krause A, Schicke B, Kuchenbecker J, Gromnica-Ihle E. Do temporal artery duplex ultrasound findings correlate with ophthalmic complications in giant cell arteritis? Rheumatology. 2009;48:383\u20135. https:\/\/doi.org\/10.1093\/rheumatology\/ken515.","journal-title":"Rheumatology"},{"key":"4254_CR43","doi-asserted-by":"publisher","first-page":"309EP","DOI":"10.3899\/jrheum.140188","volume":"42","author":"AG Singh","year":"2015","unstructured":"Singh AG, Kermani TA, Crowson CS, Weyand CM, Matteson EL, Warrington KJ. Visual manifestations in giant cell arteritis: trend over 5 decades in a population-based cohort. J Rheumatol. 2015;42:309EP\u2013315. https:\/\/doi.org\/10.3899\/jrheum.140188.","journal-title":"J Rheumatol"},{"key":"4254_CR44","doi-asserted-by":"publisher","first-page":"411EP","DOI":"10.1177\/10815589231152821","volume":"71","author":"LM Smith","year":"2023","unstructured":"Smith LM, Alvarado LA, Dihowm F. The incidence and characteristics of giant cell arteritis in Hispanics and the associated outcomes of ischemic ocular events and stroke. J Invest Med. 2023;71:411EP\u2013418. https:\/\/doi.org\/10.1177\/10815589231152821.","journal-title":"J Invest Med"},{"key":"4254_CR45","doi-asserted-by":"publisher","first-page":"129EP","DOI":"10.1080\/01658107.2023.2175874","volume":"47","author":"E Sun","year":"2023","unstructured":"Sun E, Li X, Gruener AM, Chang JR, Eberhart CG, Henderson AD, et al. Presenting features of giant cell arteritis with active versus healed arteritis on biopsy. Neuro Ophthalmol. 2023;47:129EP\u2013135. https:\/\/doi.org\/10.1080\/01658107.2023.2175874.","journal-title":"Neuro Ophthalmol"},{"key":"4254_CR46","doi-asserted-by":"publisher","first-page":"504EP","DOI":"10.1097\/WNO.0000000000001817","volume":"43","author":"E Sun","year":"2023","unstructured":"Sun E, Li X, Gruener AM, Chang JR, Henderson AD, Carey AR. Baseline characteristics and clinical presentation of biopsy-proven giant cell arteritis in white compared with black patients. J Neuro Ophthalmol. 2023;43:504EP\u2013508. https:\/\/doi.org\/10.1097\/WNO.0000000000001817.","journal-title":"J Neuro Ophthalmol"},{"key":"4254_CR47","doi-asserted-by":"publisher","first-page":"152071","DOI":"10.1016\/j.semarthrit.2022.152071","volume":"56","author":"P Therkildsen","year":"2022","unstructured":"Therkildsen P, de Thurah A, Faurschou M, Baslund B, Hansen IT, N\u00f8rgaard M, et al. A nationwide study of ocular manifestations leading to hospital contacts among patients with giant cell arteritis. Semin Arthritis Rheum. 2022;56:152071. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152071.","journal-title":"Semin Arthritis Rheum"},{"key":"4254_CR48","doi-asserted-by":"publisher","first-page":"59EP","DOI":"10.1080\/03009742.2021.1889025","volume":"51","author":"A Tomelleri","year":"2022","unstructured":"Tomelleri A, Campochiaro C, Sartorelli S, Farina N, Baldissera E, Dagna L. Presenting features and outcomes of cranial-limited and large-vessel giant cell arteritis: a retrospective cohort study. Scand J Rheumatol. 2022;51:59EP\u201366. https:\/\/doi.org\/10.1080\/03009742.2021.1889025.","journal-title":"Scand J Rheumatol"},{"key":"4254_CR49","doi-asserted-by":"publisher","first-page":"60EP","DOI":"10.1080\/01658107.2024.2389934","volume":"49","author":"SM Tucker","year":"2025","unstructured":"Tucker SM, Haas SJ, Zaihra Rizvi T. Predictors of Permanent vision loss in giant cell arteritis. Neuro Ophthalmol. 2025;49:60EP\u201368. https:\/\/doi.org\/10.1080\/01658107.2024.2389934.","journal-title":"Neuro Ophthalmol"},{"key":"4254_CR50","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13075-020-02377-8","volume":"23","author":"S Unizony","year":"2021","unstructured":"Unizony S, McCulley TJ, Spiera R, Pei J, Sidiropoulos PN, Best JH, et al. Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations. Arthritis Res Ther. 2021;23:8 https:\/\/doi.org\/10.1186\/s13075-020-02377-8.","journal-title":"Arthritis Res Ther"},{"key":"4254_CR51","doi-asserted-by":"publisher","unstructured":"Vincenten SCC, Mulleners WM. The quest for a headache pattern in giant cell arteritis: a cohort study. Cephalalgia Reports 2021;4 ((Vincenten, Mulleners) Canisius Wilhelmina Ziekenhuis (CWZ), Department of Neurology (C19), Nijmegen, Netherlands). 2024. https:\/\/doi.org\/10.1177\/25158163211024134.","DOI":"10.1177\/25158163211024134"},{"key":"4254_CR52","doi-asserted-by":"publisher","first-page":"617EP","DOI":"10.1016\/0002-9394(58)92165-2","volume":"45","author":"HP Wagener","year":"1958","unstructured":"Wagener HP, Hollenhorst RW. The ocular lesions of temporal arteritis. Am J Ophthalmol. 1958;45:617EP\u2013630.","journal-title":"Am J Ophthalmol"},{"key":"4254_CR53","doi-asserted-by":"publisher","first-page":"60EP","DOI":"10.1159\/000449466","volume":"3","author":"AL Wang","year":"2017","unstructured":"Wang AL, Raven ML, Surapaneni K, Albert DM. Studies on the histopathology of temporal arteritis. Ocul Oncol Pathol. 2017;3:60EP\u201365. https:\/\/doi.org\/10.1159\/000449466.","journal-title":"Ocul Oncol Pathol"},{"key":"4254_CR54","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1136\/bjo.47.9.555","volume":"47","author":"AG Whitfield","year":"1963","unstructured":"Whitfield AG, Bateman M, Cooke WT. Temporal arteritis. Br J Ophthalmol. 1963;47:555\u201366. https:\/\/doi.org\/10.1136\/bjo.47.9.555.","journal-title":"Br J Ophthalmol"},{"key":"4254_CR55","doi-asserted-by":"publisher","first-page":"97EP","DOI":"10.2147\/OARRR.S336925","volume":"14","author":"P Wurmann","year":"2022","unstructured":"Wurmann P, Karsulovic C, Sabugo F, Hernandez C, Soto PZ, Mac-Namara M. Cranial versus extracranial involvement in giant cell arteritis: 15 years retrospective cohort analysis. Open Access Rheumatol. 2022;14:97EP\u2013101. https:\/\/doi.org\/10.2147\/OARRR.S336925.","journal-title":"Open Access Rheumatol"},{"key":"4254_CR56","doi-asserted-by":"publisher","first-page":"483EP","DOI":"10.4065\/79.4.483","volume":"79","author":"BR Younge","year":"2004","unstructured":"Younge BR, Cook BE Jr, Bartley GB, Hodge DO, Hunder GG. Initiation of glucocorticoid therapy: before or after temporal artery biopsy? Mayo Clin Proc. 2004;79:483EP\u2013491. https:\/\/doi.org\/10.4065\/79.4.483.","journal-title":"Mayo Clin Proc"},{"key":"4254_CR57","first-page":"ED000142","volume":"2019","author":"M Cumpston","year":"2019","unstructured":"Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane database Syst Rev. 2019;2019:ED000142.","journal-title":"Cochrane database Syst Rev"},{"key":"4254_CR58","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s40300-021-00211-y","volume":"79","author":"D B\u00f6hning","year":"2021","unstructured":"B\u00f6hning D, Holling H, B\u00f6hning W, Sangnawakij P. Investigating heterogeneity in meta-analysis of studies with rare events: estimating the amount of heterogeneity. Metron. 2021;79:259\u201372.","journal-title":"Metron"},{"key":"4254_CR59","first-page":"23","volume":"5","author":"P Patil","year":"2013","unstructured":"Patil P, Karia N, Jain S, Dasgupta B. Giant cell arteritis: a review. Eye Brain. 2013;5:23\u201333.","journal-title":"Eye Brain"},{"key":"4254_CR60","doi-asserted-by":"publisher","first-page":"479","DOI":"10.46497\/ArchRheumatol.2024.10528","volume":"39","author":"H Sawada","year":"2024","unstructured":"Sawada H, Nishimura Y, Tamaki H. Sixth cranial nerve palsy in giant cell arteritis: a systematic review. Arch Rheumatol. 2024;39:479\u201387.","journal-title":"Arch Rheumatol"},{"key":"4254_CR61","doi-asserted-by":"publisher","first-page":"236","DOI":"10.5603\/FM.2015.0037","volume":"74","author":"G Wysiadecki","year":"2015","unstructured":"Wysiadecki G, Orkisz S, Galazkiewicz-Stolarczyk M, Brzezinski P, Polguj M, Topol M. The abducens nerve: its topography and anatomical variations in intracranial course with clinical commentary. Folia Morphol. 2015;74:236\u201344. https:\/\/doi.org\/10.5603\/FM.2015.0037.","journal-title":"Folia Morphol"},{"key":"4254_CR62","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.revmed.2025.02.013","volume":"46","author":"R Deshayes","year":"2025","unstructured":"Deshayes R, Aguilar J, Mineur G, Collot R, Espitia O, Agard C. Une art\u00e9rite \u00e0 cellules g\u00e9antes r\u00e9v\u00e9l\u00e9e par une ophtalmopl\u00e9gie internucl\u00e9aire bilat\u00e9rale. La Rev de M\u00e9d Interne. 2025;46:352\u20134.","journal-title":"La Rev de M\u00e9d Interne"},{"key":"4254_CR63","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.3390\/jcm11071997","volume":"11","author":"E H\u00e9ron","year":"2022","unstructured":"H\u00e9ron E, Sedira N, Dahia O, Jamart C. Ocular complications of giant cell arteritis: an acute therapeutic emergency. J Clin Med. 2022;11:1997.","journal-title":"J Clin Med"},{"key":"4254_CR64","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1136\/practneurol-2014-000834","volume":"14","author":"JR Mitchell","year":"2014","unstructured":"Mitchell JR, Krashin-Bichler I, Rosenblum M, Diamond EL, Dinkin MJ. Giant cell arteritis presenting with bilateral orbital inflammatory disease and enhancing superficial temporal arteries. Pr Neurol. 2014;14:446\u20137. https:\/\/doi.org\/10.1136\/practneurol-2014-000834.","journal-title":"Pr Neurol"},{"key":"4254_CR65","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/WNO.0000000000000116","volume":"34","author":"MJ Thurtell","year":"2014","unstructured":"Thurtell MJ, Longmuir RA. Third nerve palsy as the initial manifestation of giant cell arteritis. J Neuro Ophthalmol. 2014;34:243\u20135.","journal-title":"J Neuro Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04254-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04254-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04254-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T11:38:51Z","timestamp":1774352331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04254-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4254"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04254-1","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"27 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was exempt from institutional review board approval (under article 2.4 of the Tri-Council Policy Statement) as the data was extracted in its entirety from published primary research. The dissemination of results will not identify any individual or generate new forms of identifiable information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}